RadNet
- Market cap
- 5.40B
- P/E (TTM)i
- -263.88
- P/Bi
- 4.93
- EPSi
- -0.25
- Div yieldi
- 0.00%
- 52W posi
- 51%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| RadNet (RDNT) | 5.40B | -263.88 | 4.93 | 0.00% |
| Thermo Fisher Scientific (TMO) | 244.79B | 35.63 | 4.65 | 0.27% |
| Danaher (DHR) | 153.60B | 38.81 | 2.92 | 0.66% |
| Natera (NTRA) | 57.02B | -293.01 | 31.30 | 0.00% |
| Agilent Technologies (A) | 47.67B | 33.35 | 6.47 | 0.60% |
| Waters (WAT) | 42.84B | 110.38 | 2.82 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 16.7% below Morningstar's fair value estimate.
Fair value
RadNet Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $80.04 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's balance sheet bolsters our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of 4.7, which sits in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.
Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.9%, a core component of profitability, ranks in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.